TARS Tarsus Pharmaceuticals, Inc.
$73.01
Tarsus Pharmaceuticals, Inc. (TARS) Earnings News
Earnings press releases, previews and reviews for Tarsus Pharmaceuticals, Inc. (TARS), newest first. Our most recent is review: Tarsus Beats as XDEMVY Guidance Rises Again, but a $632 Million Pipeline Bet Reshapes the Balance Sheet.
Tuesday
November 3, 2026
8:23 PM ET
Tarsus Beats as XDEMVY Guidance Rises Again, but a $632 Million Pipeline Bet Reshapes the Balance Sheet
Earnings Whispers · Review
Tuesday
November 3, 2026
4:05 PM ET
Tarsus Reports Third Quarter 2026 Financial Results
Friday
October 30, 2026
9:30 AM ET
Tarsus Must Show Xtemvi Can Outrun Its Pricier Retina Ambitions in Q3
Earnings Whispers · Preview
Thursday
October 29, 2026
4:30 PM ET
Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
Thursday
August 6, 2026
7:03 AM ET
Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
Wednesday
August 5, 2026
8:02 PM ET
Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026